ACU
Acme United Corporation
ACU has lower modeled downside risk, despite its lower overall score.
CELH
Celsius Holdings, Inc.
CELH has the edge over ACU overall, supported by stronger valuation and stronger fundamentals.
ACU Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Healthy |
ACU's revenue, profitability, cash flow and balance sheet are all currently healthy.
CELH Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Strong |
CELH's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
ACU PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.6x | $26.07 | -63% |
| Fair | 15x | $41.79 | -40% |
| Expensive | 23x | $62.14 | -12% |
| Forward | 23x | $70.22 | — |
| Current | 26x | $70.22 | — |
Historical ranges are pointers, not guarantees.
ACU's PE is in its expensive range at 26x. If earnings grow as analysts expect, today's price would be 23x next year's earnings.
CELH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 21x | $31.89 | — |
| Current | 35x | $31.89 | — |
| Cheap | 40x | $35.95 | +13% |
| Fair | 141x | $127 | +299% |
| Expensive | 650x | $585 | +1735% |
Historical ranges are pointers, not guarantees.
CELH has the edge over ACU in the historical PE scenario, which offers more potential upside but is not a forecast.
ACU Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for ACU, with profitability improving.
CELH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for CELH, with profitability improving. However, they disagree widely on these estimates.
ACU Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.12 | +15% |
| Q3 2026 | $2.72 | +11% |
| Q2 2026 | $2.38 | -6.3% |
| Q1 2026 | $2.32 | -6.1% |
| Q4 2025 | $2.49 | +1.6% |
| Q3 2025 | $2.46 | -51% |
| Q2 2025 | $2.54 | -50% |
| Q1 2025 | $2.47 | -50% |
| Q4 2024 | $2.45 | -50% |
ACU has the edge over CELH on earnings, with stronger typical year-over-year growth.
CELH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.53 | +70% |
| Q3 2026 | $0.90 | +718% |
| Q2 2026 | $0.24 | -37% |
| Q1 2026 | $0.43 | +30% |
| Q4 2025 | $0.25 | -44% |
| Q3 2025 | $0.11 | -85% |
| Q2 2025 | $0.38 | -62% |
| Q1 2025 | $0.33 | -64% |
| Q4 2024 | $0.45 | -42% |
CELH earned $0.90 per share over the past year, about eight times what it earned the year before.
ACU Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $58M | +18% |
| Q2 2026 | $62.7M | +16% |
| Q1 2026 | $52.3M | +14% |
| Q4 2025 | $47.5M | +3.4% |
| Q3 2025 | $49.1M | +1.9% |
| Q2 2025 | $54M | -2.6% |
| Q1 2025 | $46M | +2.2% |
| Q4 2024 | $45.9M | +9.5% |
ACU's revenue has grown year over year for five quarters in a row: $58M last quarter, up 18% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7.7% | +1.6 points |
| Q2 2026 | 11% | -0.9 points |
| Q1 2026 | 3.3% | -1.9 points |
| Q4 2025 | 6.1% | +1.1 points |
| Q3 2025 | 6.1% | +0.1 points |
| Q2 2025 | 12% | +0.3 points |
| Q1 2025 | 5.3% | -0.4 points |
| Q4 2024 | 5% | 0 points |
ACU's operating margin was 7.7% last quarter, up 1.6 points from the same quarter a year ago.
CELH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $847.2M | +17% |
| Q2 2026 | $817.9M | +11% |
| Q1 2026 | $782.6M | +138% |
| Q4 2025 | $721.6M | +117% |
| Q3 2025 | $725.1M | +173% |
| Q2 2025 | $739.3M | +84% |
| Q1 2025 | $329.3M | -7.4% |
| Q4 2024 | $332.2M | -4.4% |
CELH's revenue has grown year over year for six quarters in a row: $847M last quarter, up 17% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +31 points |
| Q2 2026 | 9.2% | -10 points |
| Q1 2026 | 18% | +2 points |
| Q4 2025 | 3.6% | +9.2 points |
| Q3 2025 | -11% | -9.8 points |
| Q2 2025 | 19% | -4.1 points |
| Q1 2025 | 16% | -7.6 points |
| Q4 2024 | -5.6% | -23 points |
CELH has the edge over ACU on profitability, with a higher operating margin.
ACU Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.4M | -558% |
| Q2 2026 | $12.1M | +156% |
| Q1 2026 | -$4.1M | +$568K |
| Q4 2025 | $7.3M | +55% |
| Q3 2025 | $301K | -96% |
| Q2 2025 | $4.7M | +7% |
| Q1 2025 | -$4.7M | +$7.1M |
| Q4 2024 | $4.7M | -23% |
ACU has the edge over CELH on cash flow, with more consistent year-over-year improvement.
CELH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $127.7M | -60% |
| Q2 2026 | $205.5M | +479% |
| Q1 2026 | $65.8M | -32% |
| Q4 2025 | -$130M | -285% |
| Q3 2025 | $321.5M | +3599% |
| Q2 2025 | $35.5M | +17% |
| Q1 2025 | $96.4M | -26% |
| Q4 2024 | $70.3M | +16394% |
CELH still generates free cash flow, though less than at its 2025 peak: $269M over the past year.
ACU Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.7% | +155K shares |
| 1 year | +3.1% | +128K shares |
| 3 years | +15% | +575K shares |
| 5 years | +5.9% | +238K shares |
| Available history | +24% | +843K shares |
ACU has 4M diluted shares, up 3.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | $12.00 |
| Q3 2020 | — |
| Q2 2020 | $73,000 |
| Q1 2020 | $214,000 |
CELH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.8% | -2M shares |
| 1 year | -1.1% | -2.9M shares |
| 3 years | +7.4% | +17.6M shares |
| 5 years | +8.3% | +19.5M shares |
| Available history | +32% | +62.4M shares |
CELH has the edge over ACU on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $300,000 |
| Q2 2026 | $1M |
| Q1 2026 | $8.8M |
| Q4 2025 | $2.5M |
| Q3 2025 | $448,000 |
| Q2 2025 | $879,000 |
| Q1 2025 | $1.9M |
| Q4 2024 | $603,000 |
CELH spent $13M buying back its own shares over the past year, about three times what it spent the year before.
ACU Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.9x | Very low |
| Q2 2026 | 0.8x | Very low |
| Q1 2026 | 1.4x | Healthy |
| Q4 2025 | 0.4x | Very low |
| Q3 2025 | 0.6x | Very low |
| Q2 2025 | 0.6x | Very low |
| Q1 2025 | 0.8x | Very low |
| Q4 2024 | 0.6x | Very low |
ACU's net debt is less than a year of its operating earnings (EBITDA).
CELH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.1x | Net Cash |
| Q2 2026 | 0.2x | Very low |
| Q1 2026 | 0.5x | Very low |
| Q4 2025 | 1.6x | Healthy |
| Q3 2025 | 0.5x | Very low |
| Q2 2025 | 1.4x | Healthy |
| Q1 2025 | -7.3x | Net Cash |
| Q4 2024 | -5.5x | Net Cash |
CELH has the edge over ACU on leverage, with a lower net debt burden relative to earnings.
ACU Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 79.3 | Overbought |
| Stochastic | 83.4 | Overbought |
ACU's weekly RSI is 79 (overbought) and its Stochastic is 83 (overbought).
CELH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.3 | Neutral |
| Stochastic | 56.8 | Neutral |
CELH's weekly RSI is 51 (neutral) and its Stochastic is 57 (neutral).
ACU PE vs Consumer Defensive Sector
| Metric | ACU | Sector median | Relative |
|---|---|---|---|
| PE | 26x | 19x | 32% above |
| PE % | 88 | 18 | 70 pts above |
ACU has the edge over CELH on valuation relative to its sector.
CELH PE vs Consumer Defensive Sector
| Metric | CELH | Sector median | Relative |
|---|---|---|---|
| PE | 35x | 19x | 82% above |
| PE % | 11 | 18 | 7 pts below |
CELH is trading at 35x earnings, a 82% premium to the Consumer Defensive sector's median of 19x.
ACU Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $64.9 | 8.2% above |
| 20 week MA | $59.9 | 17% above |
| 50 week MA | $49.8 | 41% above |
| 100 week MA | $44.6 | 57% above |
| 200 week MA | $39.9 | 76% above |
ACU has the edge over CELH on trend strength, trading above more of its moving averages.
CELH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.1 | 9.4% above |
| 20 week MA | $29.6 | 7.8% above |
| 50 week MA | $36.1 | 12% below |
| 100 week MA | $38.8 | 18% below |
| 200 week MA | $44.6 | 29% below |
CELH has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 29% below its 200-week average.
ACU Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $23.7 | $31.2 | +32% |
| 2021 | $31.2 | $35.6 | +14% |
| 2022 | $35.6 | $22.3 | -37% |
| 2023 | $22.3 | $42.9 | +92% |
| 2024 | $42.9 | $36.8 | -14% |
| 2025 | $36.8 | $40.6 | +10% |
| 2026 YTD | $40.6 | $70.2 | +73% |
ACU has the edge over CELH on returns for 2026, with the stronger performance.
CELH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.58 | $14.7 | +832% |
| 2021 | $14.7 | $24.9 | +69% |
| 2022 | $24.9 | $35.6 | +43% |
| 2023 | $35.6 | $54.5 | +53% |
| 2024 | $54.5 | $26.5 | -51% |
| 2025 | $26.5 | $45.6 | +72% |
| 2026 YTD | $45.6 | $31.9 | -30% |
CELH's yearly returns have swung widely, from +832% in 2020 to −51% in 2024. It's down 30% so far in 2026.